Candidiasis Therapeutics Market 2026

November 2025 | 200 pages | ID: C0199C73D659EN
DataM Intelligence

Abstracts

The Candidiasis Therapeutics Market was valued at in and is anticipated to reach by , at a CAGR of 0.053 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Candidiasis Therapeutics Market.

This report delivers a comprehensive overview of the Candidiasis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Candidiasis Therapeutics Market. The Candidiasis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

Candidiasis Therapeutics Market Scope:

Major Highlights

This report delivers a comprehensive overview of the Candidiasis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Candidiasis Therapeutics Market. The Candidiasis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. GLOBAL CANDIDIASIS THERAPEUTICS MARKET METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DEFINITION AND OVERVIEW

3. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - EXECUTIVE SUMMARY

3.1. Market Snippet by Type
3.2. Market Snippet by Drug Class
3.3. Market Snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region

4. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing number of patients affected by candidiasis infection
    4.1.1.2. Growing awareness of candidiasis infection
    4.1.1.3. XX
  4.1.2. Restraints:
    4.1.2.1. Availability of alternative treatments
    4.1.2.2. Side-effects caused by the drugs
    4.1.2.3. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - INDUSTRY ANALYSIS

5.1. Epidemiology
5.2. Pipeline Analysis
5.3. Porter's Five Forces Analysis
5.4. Supply Chain Analysis
5.5. Clinical Trials
5.6. Pricing Analysis
5.7. Regulatory Analysis
5.8. Reimbursement Analysis
5.9. Unmet Needs

6. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  7.1.2. Market Attractiveness Index, By Type Segment
7.2. Oral Candidiasis*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Vulvovaginal Candidiasis
7.4. Cutaneous Candidiasis
7.5. Invasive Candidiasis
7.6. Systemic Candidiasis

8. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DRUG CLASS

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  8.1.2. Market Attractiveness Index, By Drug Class Segment
8.2. Polyene*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  8.2.3. Nystatin (Mycostatin and others)
  8.2.4. Amphotericin B (Fungizone, Amphocin)
8.3. Azole Antifungals
  8.3.1. Fluconazole (Diflucan)
  8.3.2. Itraconazole (Sporanox)
  8.3.3. Voriconazole (Vfend)
  8.3.4. Posaconazole (Noxafil)
8.4. Topical azoles
  8.4.1. Clotrimazole (Mycelex, Femizole-7)
  8.4.2. Butoconazole (Femstat-3, Gynazole-1)
  8.4.3. Miconazole vaginal (Monistat, Micatin)
  8.4.4. Tioconazole (Vagistat-1)
  8.4.5. Terconazole vaginal (Terazol-7, Terazol-3)
8.5. Glucan synthesis inhibitors (echinocandins)
  8.5.1. Caspofungin (Cancidas)
  8.5.2. Micafungin (Mycamine)
  8.5.3. Anidulafungin (Eraxis)
8.6. Antimetabolite
  8.6.1. Flucytosine (Ancobon)
8.7. Allylamines
  8.7.1. Terbinafine (Daskil, Lamisil)
8.8. Others

9. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY ROUTE OF ADMINISTRATION

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  9.1.2. Market Attractiveness Index, By Route of Administration Segment
9.2. Oral*
  9.2.1. Introduction
  9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Parenteral
9.4. Topical

10. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DISTRIBUTION CHANNEL

10.1. Introduction
  10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacies*
  10.2.1. Introduction
  10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Others

11. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. The U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. The U.K.
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of key companies to watch
12.5. List of the company with disruptive technology
12.6. List of start-up companies

13. GLOBAL CANDIDIASIS THERAPEUTICS MARKET- COMPANY PROFILES

13.1. Cidara Therapeutics Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. NovaDigm Therapeutics Inc
13.3. Amplyx Pharmaceuticals Inc.
13.4. Astellas Pharma Inc.
13.5. Basilea Pharmaceutica Ltd.
13.6. Grupo Ferrer Internacional, S.A.
13.7. Pacgen Biopharmaceuticals
13.8. Viamet Pharmaceuticals Holdings, LLC
13.9. Mycovia Pharmaceuticals Inc
13.10. Novabiotics Limited
13.11. Bayer AG
13.12. Biomar Microbial Technologies
13.13. Merck
13.14. Scynexis Inc.
13.15. Pfizer, Inc. (*LIST NOT EXHAUSTIVE)

14. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - DATAM

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us